Humatin Kapseln

Humatin Kapseln is an oral capsule containing paromomycin sulfate as the active ingredient. It is a prescription‑only aminoglycoside antibiotic marketed in the European Union. The formulation delivers a standardized amount of paromomycin sulfate per capsule and is intended for systemic use under medical supervision. Humatin Kapseln belongs to the antiprotozoal therapeutic class and is identified by ATC code J01XX07 and is regulated according to EU pharmaceutical standards.

Humatin Kapseln is prescribed for the treatment of several protozoal infections where paromomycin sulfate has demonstrated efficacy.

- Amebiasis caused by Entamoeba histolytica, particularly intestinal disease and liver abscesses. - Giardiasis due to Giardia lamblia, especially in travelers and immunocompromised patients. - Cutaneous and visceral leishmaniasis caused by Leishmania species, used when other options are limited. - Cryptosporidiosis in patients with persistent diarrhea, often in HIV‑positive individuals. - Other intestinal protozoal infections such as balantidiasis or microsporidiosis when susceptibility is confirmed.

Adverse reactions to Humatin Kapseln are generally mild and reversible, but clinicians should be aware of less frequent but potentially serious events that may require medical attention.

Common: - Nausea, vomiting, or abdominal discomfort that usually resolves after treatment completion. - Loose stools or mild diarrhea, occasionally accompanied by cramping. - A metallic or altered taste sensation (dysgeusia) that may affect appetite. - Headache, light‑headedness, or transient dizziness without neurological deficit.

Serious: - Severe allergic reactions, including widespread rash, itching, swelling, or anaphylactic shock. - Ototoxic effects such as tinnitus, ringing in the ears, or progressive hearing loss, especially with high cumulative exposure. - Nephrotoxic manifestations, including increased serum creatinine, reduced glomerular filtration rate, or oliguria.

Before prescribing Humatin Kapseln, healthcare providers should evaluate several safety considerations to minimize risk.

- Assess renal function; dose adjustment may be needed in patients with impaired clearance. - Monitor auditory function, particularly in patients receiving prolonged therapy or high doses. - Use caution in pregnant or breastfeeding women; the drug crosses the placenta and may be excreted in milk. - Review patient history for hypersensitivity to aminoglycosides or other antibiotics. - Avoid concomitant use of other nephrotoxic or ototoxic agents whenever possible. - Consider baseline liver enzymes in patients with pre‑existing hepatic disease.

Paromomycin sulfate can interact with other medicines, affecting efficacy or increasing toxicity.

Avoid: - Concurrent use with other aminoglycosides (e.g., gentamicin, amikacin) due to additive ototoxic and nephrotoxic risk. - Co‑administration with loop diuretics such as furosemide, which may potentiate renal toxicity. - Combining with potent neuromuscular blockers (e.g., pancuronium) that can enhance muscle weakness.

Use with caution: - Use cautiously with drugs cleared renally (e.g., vancomycin, cisplatin) and monitor renal function. - Caution when given with other ototoxic agents (e.g., vancomycin, loop diuretics) and perform audiometric testing. - Adjust dose when taken with medications that alter intestinal pH, such as antacids, which may affect absorption.